Sofosbuvir and ribavirin before liver re-transplantation for graft failure due to recurrent hepatitis C: a case report.

Détails

Ressource 1Télécharger: 25887762_BIB_2416C6CBDE27.pdf (377.54 [Ko])
Etat: Public
Version: de l'auteur
ID Serval
serval:BIB_2416C6CBDE27
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Etude de cas (case report): rapporte une observation et la commente brièvement.
Collection
Publications
Titre
Sofosbuvir and ribavirin before liver re-transplantation for graft failure due to recurrent hepatitis C: a case report.
Périodique
BMC Gastroenterology
Auteur(s)
Vionnet J., Pascual M., Chtioui H., Giostra E., Majno P.E., Decosterd L.A., Moradpour D.
ISSN
1471-230X (Electronic)
ISSN-L
1471-230X
Statut éditorial
Publié
Date de publication
2015
Peer-reviewed
Oui
Volume
15
Numéro
1
Pages
38
Langue
anglais
Notes
Publication types: Journal Article Publication Status: epublish
Résumé
BACKGROUND: Recurrent hepatitis C virus infection after liver transplantation is associated with reduced graft and patient survival. Re-transplantation for graft failure due to recurrent hepatitis C is controversial and not performed in all centers.
CASE PRESENTATION: We describe a 54-year-old patient with hepatitis C virus genotype 1b infection and a null response to pegylated interferon-α and ribavirin who developed decompensated graft cirrhosis 6 years after a first liver transplantation. Treatment with sofosbuvir and ribavirin allowed for rapid negativation of serum HCV RNA and was well tolerated despite advanced liver and moderate renal dysfunction. Therapeutic drug monitoring did not reveal any clinically significant drug-drug interactions. Despite virological response, the patient remained severely decompensated and re-transplantation was performed after 46 days of undetectable serum HCV RNA. The patient is doing well 12 months after his second liver transplantation and remains free of hepatitis C virus.
CONCLUSIONS: The use of directly acting antivirals may allow for successful liver re-transplantation for recipients who remain decompensated despite virological response and is likely to improve the outcome of liver re-transplantation for end-stage recurrent hepatitis C.
Pubmed
Web of science
Open Access
Oui
Création de la notice
28/04/2015 17:15
Dernière modification de la notice
20/08/2019 13:02
Données d'usage